Phase III Trial Results for Ally-1 Reveal High HCV Cure Rates | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Merck's Hepatitis C Drug Works

Back to News Homepage
Next

Delaying Hepatitis C Treatment Could Be Detrimental

Phase III Trial Results for Ally-1 Reveal High HCV Cure Rates

The Editors at Hepatitis Central
April 26, 2015

Print this page

New daclatasvir/sofosbuvir/ribavirin treatment showing promising trial results.
Pin it on Pinterest

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

97% of post-transplant patients with HCV genotype 1a achieved cure

91% of post-transplant patients with HCV genotype 3 achieved cure  

No need seen to alter existing transplantation medication regimens

(PRINCETON, N.J., APRIL 25, 2015)Bristol-Myers Squibb Company (NYSE:BMY) today announced that primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) with either advanced cirrhosis or post-liver transplant recurrence of HCV. The data was presented as a late-breaker at The International Liver Congress™ 2015, the 50th annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria from April 22-26.

“The results of the ALLY-1 trial point to the potential of this investigational daclatasvir-based regimen in a patient population with high unmet needs despite recent advances in hepatitis C treatment,” said Fred Poordad, M.D., ALLY-1 Lead Investigator and Clinical Professor of Medicine, Chief, Hepatology, University of Texas Health Science Center and VP, Academic and Clinical Affairs Texas Liver Institute. “Transplant patients take a variety of immunosuppressive medications to prevent organ rejection; that complicates the treatment of hepatitis C. In ALLY-1, we saw no drug-drug interactions between transplant and hepatitis C therapies and no need to make dose adjustments to patients’ transplant-related drugs while they received the daclatasvir-based regimen that resulted in high SVR12 rates.”

Continue reading this article:
http://news.bms.com/press-release/ally-1-trial-results-show-investigational-daclatasvir-based-regimen-cures-94-post-live
 

No Comments - be the first!
Share
Share
Previous

Merck's Hepatitis C Drug Works

Back to News Homepage
Next

Delaying Hepatitis C Treatment Could Be Detrimental

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.